We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > AML trial

News List

Trovagene Completes Dosing of Patients Treated with Onvansertib, Decitabine in AML Trial americanpharmaceuticalreview
September 28, 2018
Trovagene announced completion of the second dosing cohort of Onvansertib, its first-in-class, 3rd generation, highly-selective oral Polo-like Kinase 1 (PLK1) Inhibitor, in combination with standard-of-care decitabine, in its Phase 1b/2 clinical trial in
Tolero Pharmaceuticals collaborates with AbbVie for AML trial biospectrumasia
August 21, 2018
Under the terms of the agreement, Tolero and AbbVie will equally share all development expenses. Tolero will retain full commercial rights for alvocidib and AbbVie will retain full commercial rights for venetoclax.